Vanguard Capital Management
KYNB

Vanguard Capital Management’s Kyntra Bio KYNB Stock Holding History

Vanguard Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21M Buy
159,950
+3,343
+2% +$23.4K ﹤0.01% 3558
2026
Q1 		$1.06M Buy
+156,607
New +$1.23M ﹤0.01% 3536

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management's KYNB Position: Q2 2026 in Review

Vanguard Capital Management increased its Kyntra Bio (KYNB) stake by 2.1% in Q2 2026, buying an estimated $23.4K and bringing the position to 159,950 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #3558.

Vanguard Capital Management first reported a position in KYNB in Q1 2026 and has held it in 2 quarters since. 27 funds tracked by Wall St. Rank hold KYNB as of Q2 2026.

  • Vanguard Capital Management held 159,950 shares of Kyntra Bio worth $1.21M as of Q2 2026.
  • Vanguard Capital Management bought 3,343 Kyntra Bio shares in Q2 2026, an estimated $23.4K.
  • Kyntra Bio made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3558 holding.
  • Vanguard Capital Management first reported a position in Kyntra Bio in Q1 2026 and has held it in 2 quarters since.
  • 27 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.